Collaborative Arrangements and Licensing Agreements, Alnylam Pharmaceuticals, Inc. (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue		$ 810,456	$ 729,264	$ 1,122,599
R&D Revenue [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue		468,061	364,565	$ 770,149
Alnylam [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Award from arbitration panel	$ 41,200
Revenue	41,200
Deferred revenue	$ 0	$ 0	$ 0
Alnylam [Member] | Revenue [Member] | Strategic Partner [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Concentration percentage		0.00%	7.00%	2.00%
Alnylam [Member] | R&D Revenue [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue		$ 0	$ 47,900	$ 24,100